anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: We hypothesized that analysis of serial ECGs could predict new-onset atrial fibrillation (AF) more accurately than analysis of a single ECG by detecting the subtle cardiac remodeling that occurs immediately before AF occurrence. Our aim in this study was to compare the performance of 2 types of machine learning (ML) algorithms.
METHODS AND RESULTS: Standard 12-lead ECGs of patients selected by cardiologists between January 2010 and May 2021 were used for ML model development. Two ML models (single ECG and serial ECG) were developed using a light gradient boosting machine-learning algorithm. Model performance was evaluated based on the area under the receiver operating characteristic curve, sensitivity, specificity, accuracy, and F1 score. We trained the ML models on 415 964 ECGs from 176 090 patients. When testing the 2 ML models using external validation data sets, the performance of the serial-ML model was significantly better than that of the single-ML model for predicting new-onset AF (single- versus serial-ML model: sensitivity 0.744 versus 0.810; specificity 0.742 versus 0.822; accuracy 0.743 versus 0.816; F1 score 0.743 versus 0.815; area under the receiver operating characteristic curve 0.812 versus 0.880; P<0.001). The Shapley Additive Explanations analysis ranked P-wave duration and amplitude among the top 10 ECG parameters.
CONCLUSIONS: An ML model based on serial ECGs from an individual had greater ability to predict new-onset AF than the ML model based on a single ECG. P-wave morphologies were associated with future AF prediction.
The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE! program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
Apheresis: On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation. Co-culture Stem Cell Infusion on Day 0. Melphalan 100 mg/m\^2 IV over 30 minutes daily on Days -2 and -1.
BACKGROUND: The scapular free flap (SFF) is essential in complex reconstructive surgery and often indicated in complex defects with compromised or poor local tissue integrity. This review aims to assess the versatility and reliability of the SFF during reconstruction.
METHODS: A comprehensive literature review of multiple databases was conducted following the PRISMA guidelines. An analysis of pooled data was performed to evaluate flap failure rate for any anatomical unit using SFF as the primary endpoints. Secondary endpoints included other complication rates after reconstruction such as partial flap loss, revision surgery, fistula, hematoma, and infection.
RESULTS: A total of 110 articles were included, with 1447 pooled flaps. The main recipient site was the head and neck region (89.0%). Major indications for reconstruction were malignancy (55.3%), burns (19.2%), and trauma (9.3%). The most common types of flaps were osteocutaneous (23.3%), cutaneous (22.6%), and chimeric (18.0%). The pooled flap failure rate was 2% (95%CI: 1%-4%). No significant heterogeneity was present across studies (Q statistic 20.2, p = .69; I2 .00%, p = .685). Nonscapular supplementary flaps and grafts were required in 61 cases. The average length and surface area of bone flaps were 7.2 cm and 24.8cm2, respectively. The average skin paddle area was 134.2cm2.
CONCLUSION: The SFF is a useful adjunct in the reconstructive surgeon's armamentarium as evidence by its intrinsic versatility and diverse clinical indications. Our data suggest a low failure rate in multicomponent defect reconstruction, especially in head and neck surgery. SFFs enable incorporation of multiple tissue types and customizable dimensions-both for vascularized bone and cutaneous skin-augmenting its value in the microsurgeon's repertoire as a chimeric flap. Further research is necessary to overcome the conventional barriers to SFF utilization and to better comprehend the specific scenarios in which the SFF can serve as the preferred alternative workhorse flap.
High-grade serous ovarian cancer remains a poorly understood disease with a high mortality rate. Although most patients respond to cytotoxic therapies, a majority will experience recurrence. This may be due to a minority of drug-resistant cancer stem-like cells (CSC) that survive chemotherapy and are capable of repopulating heterogeneous tumors. It remains unclear how CSCs are supported in the tumor microenvironment (TME) particularly during chemotherapy exposure. Tumor-associated macrophages (TAM) make up half of the immune population of the ovarian TME and are known to support CSCs and contribute to cancer progression. TAMs are plastic cells that alter their phenotype in response to environmental stimuli and thus may influence CSC maintenance during chemotherapy. Given the plasticity of TAMs, we studied the effects of carboplatin on macrophage phenotypes using both THP1- and peripheral blood mononuclear cell (PBMC)-derived macrophages and whether this supports CSCs and ovarian cancer progression following treatment. We found that carboplatin exposure induces an M1-like proinflammatory phenotype that promotes SOX2 expression, spheroid formation, and CD117+ ovarian CSCs, and that macrophage-secreted CCL2/MCP-1 is at least partially responsible for this effect. Depletion of TAMs during carboplatin exposure results in fewer CSCs and prolonged survival in a xenograft model of ovarian cancer. This study supports a role for platinum-based chemotherapies in promoting a transient proinflammatory M1-like TAM that enriches for CSCs during treatment. Improving our understanding of TME responses to cytotoxic drugs and identifying novel mechanisms of CSC maintenance will enable the development of better therapeutic strategies for high-grade serous ovarian cancer. Significance: We show that chemotherapy enhances proinflammatory macrophage phenotypes that correlate with ovarian cancer progression. Given that macrophages are the most prominent immune cell within these tumors, this work provides the foundation for future translational studies targeting specific macrophage populations during chemotherapy, a promising approach to prevent relapse in ovarian cancer.
Decision information systems, methods, and computer programs for better informing decisions to use multiple drugs in drug delivery devices, including implantable devices, for drug administration. Executable computer programs and logic embodying methods of the invention can calculate consistent multiple drug mixture amounts and drug delivery flow rates. One program accepts user input indicating a desired first drug dose rate, an initial first drug concentration, a desired second drug dose rate, an initial second drug concentration, and the reservoir size of the drug delivery device. The program method calculates a first drug amount and a second drug amount to combine in a mixture as well as a first drug true concentration in the mixture. The drugs can be mixed consistent with the physician's instructions using the program output. The first drug true concentration can be entered into a programmer device as the only drug concentration entered. Another program calculates a consistent first drug, second drug, and diluent amount to be added to a mixture for injection into a fixed flow rate, implantable drug delivery device. Methods preferably output true concentrations and dose rates for all drugs to be added and most preferably show all calculations used to arrive at the flow rate and mixture amount calculations. Yet another program receives a new desired drug dose rate for a previously filled device. The program accepts the existing mixture volume and true drug concentrations for a partially depleted device and calculates a new mixture flow rate to achieve the desired dose rate using the existing mixture. The methods can be implemented as executable computer programs in programmer devices, general purpose computers, servers, handheld computers, and personal digital assistants.
Agents for cleansing and wiping the skin, comprising jojoba oil, natural squalane and/or glycerol tri-2-ethylhexanoate.. The specified oils can be used as such or in combination with a silicone oil. The agents may if desired contain a microbicide, a pharmacologically active substance (e.g. an antiinflammatory agent), aroma substances, etc.. Pref. formulations are sprays for application to toilet or tissue paper used for wiping the circum-anal region. The spray may alternatively be applied directly to the circum-anal region before wiping with normal toilet paper. The agents may alternatively be in the form of an impregnated material, pref. paper or lint.
Language treatment will focus on improving naming deficits in people who have aphasia. An experimental group will receive treatment focusing on naming objects and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
Binder compositions are described, where the compositions include a protein, a first crosslinking compound that includes a carbohydrate, and a second crosslinking compound that includes two or more primary amine groups. The first and second crosslinking compounds may be individually crosslinkable with each other and with the protein. Also described are fiber products that may include inorganic or organic fibers and a cured thermoset binder prepared from a protein and at least two crosslinking compounds. Additionally, methods of making fiber products are described that include providing inorganic or organic fibers, and applying a liquid binder composition to the fibers to form a fiber-binder amalgam. The liquid binder composition may include a protein and at least two crosslinking compounds that include a carbohydrate and an organic amine with two or more primary amines. The amalgam may be heated to a curing temperature to form the fiber product.
EXALGO was investigated in a double-blind, placebo-controlled, randomized withdrawal study in opioid tolerant patients with moderate-to-severe low back pain. Patients were considered opioid tolerant if they were currently on opioid therapy that was ≥ 60 mg/day of oral morphine equivalent for at least 2 months prior to screening. Patients entered an open-label conversion and titration phase with EXALGO, were converted to a starting dose that was approximately 75% of their total daily morphine equivalent dose, and were dosed once daily until adequate pain control was achieved while exhibiting tolerable side effects. Supplemental immediate-release hydromorphone tablets were allowed throughout the study. Patients who achieved a stable dose entered a 12-week, double-blind, placebo-controlled, randomized treatment phase. Mean daily dose at randomization was 37.8 mg/day (range of 12 mg/day to 64 mg/day). Fifty-eight (58) percent of patients were successfully titrated to a stable dose of EXALGO during the open-label conversion and titration phase. 

During the double-blind treatment phase, patients randomized to EXALGO continued with the stable dose achieved in the conversion and titration phase of the study. Patients randomized to placebo received, in a blinded manner, EXALGO and matching placebo in doses tapering from the stable dose achieved in conversion and titration. During the taper down period, patients were allowed immediate-release hydromorphone tablets as supplemental analgesia to minimize opioid withdrawal symptoms in placebo patients. After the taper period, the number of immediate-release hydromorphone tablets was limited to two tablets per day. Forty-nine (49) percent of patients treated with EXALGO and 33% of patients treated with placebo completed the 12-week treatment period. 

EXALGO provided superior analgesia compared to placebo. There was a significant difference between the mean changes from Baseline to Week 12 or Final Visit in average weekly pain intensity Numeric Rating Scale (NRS) scores obtained from patient diaries between the two groups. The proportion of patients with various degrees of improvement from screening to Week 12 or Final Visit is shown in Figure 2. For this analysis, patients who discontinued treatment for any reason prior to Week 12 were assigned a value of zero improvement.

Figure 2. 

Percent Reduction in Average Pain Intensity from Screening   
to Week 12 or Final Visit
Group will undergo 30 sessions of aerobic exercise training over approximately 10 weeks. Sessions will require subjects to exercise on a cycle ergometer for up to 45 minutes per session.
The invention discloses a swine erysipelas protective antigen protein, wherein the amino acid sequence of the swine erysipelas protective antigen protein is shown as SEQ ID NO. 1; the nucleotide sequence of the swine erysipelas protective antigen protein after codon optimization is shown as SER ID NO. 2. The swine erysipelas protective antigen protein is composed of a SpaA recombinant protein as a main skeleton, an RspA antigen polypeptide connected with the N end of the SpaA recombinant protein through a linker, and a CbpB antigen polypeptide and a 6His tag connected with the C end of the SpaA recombinant protein. The invention also discloses a swine erysipelas subunit vaccine, which contains an effective amount of swine erysipelas protective antigen protein and a pharmaceutically acceptable adjuvant. The swine erysipelas protective antigen protein prepared by the invention has good immunogenicity, has better immune effect than 3 independent proteins and market vaccines, and has equivalent immune effect after being mixed with the three proteins; however, the immune dose of the swine erysipelas protective antigen protein prepared by the invention is lower than that of the three proteins.
PURPOSE: To obtain an agent for treating hepatitis C, administering one or more kinds of thymosins at a dose necessary for enhancing immunoresponse to mammal singly or in combination with one or more kinds of interferons used at a dose having antiviral effect. CONSTITUTION: This hepatitis C treating agent for mammal is obtained by combining an effective amount of interferon with thymosin in an amount necessary for enhancing immune system. The interferon is preferably α-, β- or γ-interferon, especially preferably interferon α-2b. An interferon produced by a recombinant DNA technique is preferably used as the interferon. An amount of interferon α used is preferably about 1×10<6> to about 10×10<6> unit. The thymosin is preferably thymosin α-1 or thymosin fraction 5. An amount of thymosin is about 1500-1700 μg of thymosin α-1. The thymosin and the interferon simultaneously or separately may be used.
The invention discloses a traditional Chinese medicine hypoglycemic formula prepared from astragalus, balsam pear, mulberry leaf, dogwood, kudzuvine root, ginseng and chromium-enriched yeast. The balsam pear known as plant insulin is used for cooling, quenching thirst, tonifying kidney and promoting urination, and the mulberry leaf known as the immortal grass is matched with the balsam pear for clearing lung, moistening dryness, suppressing hyperactive liver and improving eyesight, and the balsam pear and the immortal grass are used as monarch drugs. The ministerial drugs are ginseng and astragalus root, which are used for ascending clear yang, tonifying lung qi, regulating essence, assisting monarch drugs to strengthen primordial qi, and qi hyperactivity can promote the generation of yang fluid and the generation of body fluid can stop thirst. With the assistance of the radix puerariae, the five viscera deficiency can be compensated, and the body fluid is generated to quench thirst; the dogwood is used for tonifying liver and kidney, astringing and inducing diuresis, and has definite curative effects on thirst, dry throat, diuresis, eating and the like caused by diabetes. The chromium-enriched yeast is added to increase insulin sensitivity. The medicines are combined to play the roles of nourishing yin, promoting the secretion of saliva or body fluid, moistening dryness and quenching thirst. Clinical verification shows that the invention has the advantages of assisting in reducing blood sugar, reducing western medicine dosage, preventing the occurrence and development of diabetes complications, and being a preferred health care good product for diabetics or people with high blood sugar.
The purpose of this randomized control trial is to compare visual performance and simulated driving performance of adults with astigmatism when wearing 1\*DAY ACUVUE® MOIST for ASTIGMATISM (toric), 1\*DAY ACUVUE® MOIST (spherical control), and 1\*DAY ACUVUE® MOIST (placebo) contact lenses. Adult subjects with nearsightedness and astigmatism will wear three types of soft contact lenses (placebo, spherical and toric in randomized order). Each subject will read letters on standard eye charts and complete vision and driving tests in a driving simulator. Subjects will repeat these tests with each lens type. Analyses will include an ANOVA to look for a main effect of lens condition, and separate contrasts to compare toric vs. spherical, toric vs. placebo, and spherical vs. placebo lenses. Investigating the lenses under simulated driving conditions, which involve eye movement demands, will lend insight into the potential advantages of toric over spherical contact lenses for driving safety.
Sepsis causes significant morbidity and mortality worldwide, most surviving patients show acute or chronic mental disorders, which are known as sepsis-associated encephalopathy (SAE). SAE involves many pathological processes, including the blood-brain barrier (BBB) damage. The BBB is located at the interface between the central nervous system and the surrounding environment, which protects the central nervous system (CNS) from the invasion of exogenous molecules, harmful substances or microorganisms in the blood. Recently, a growing number of studies have indicated that the BBB destruction was involved in SAE and played an important role in SAE-induced brain injury. In the present review, we firstly reveal the pathological processes of SAE such as the neurotransmitter disorders, oxidative stress, immune dysfunction and BBB destruction. Moreover, we introduce the structure of BBB, and describe the immune cells including microglia and astrocytes that participate in the BBB destruction after SAE. Furthermore, in view of the current research on non-coding RNAs (ncRNAs), we explain the regulatory mechanism of ncRNAs including long noncoding RNAs (lncRNAs), microRNAs (miRNAs) and circular RNAs (circRNAs) on BBB in the processes of SAE. Finally, we propose some challenges and perspectives of regulating BBB functions in SAE. Hence, on the basis of these effects, both immune cells and ncRNAs may be developed as therapeutic targets to protect BBB for SAE patients.
Patients not in need of surgery treated with PD 0332991 125 mg daily for 21 consecutive days followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In the multi-center, controlled clinical trial, signs and symptoms of local cutaneous irritation were monitored in 258 acne patients who used adapalene gel, 0.3% once daily for 12 weeks. Of the patients who experienced cutaneous irritation (erythema, scaling, dryness, and/or burning/stinging), the majority of cases were mild to moderate in severity, occurred early in treatment and decreased thereafter. The incidence of local cutaneous irritation with adapalene gel, 0.3% from the controlled clinical study is provided in the following table:

Related adverse reactions from the controlled clinical trial that occurred in greater than 1% of patients who used adapalene gel, 0.3% once daily included: dry skin (14.0%), skin discomfort (5.8%), pruritus (1.9%), desquamation (1.6%), and sunburn (1.2%). The following selected adverse reactions occurred in less than 1% of patients: acne flare, contact dermatitis, eyelid edema, conjunctivitis, erythema, pruritus, skin discoloration, rash, and eczema.

In a one-year, open-label safety study of 551 patients with acne who received adapalene gel, 0.3%, the pattern of adverse reactions was similar to the 12-week controlled study.
Neurodevelopmental stimulation intervention programme combined with an oral stimulation programme. They recives 10 sesions of 15 minutes of stimulation.
This study carried out to investigate the anti-inflammatory and antinociceptive effect of tropane alkaloid (EB7) isolated from E. bezerrae. It evaluated the toxicity and possible involvement of ion channels in the antinociceptive effect of EB7, as well as its anti-inflammatory effect in adult zebrafish (Zfa). Docking studies with EB7 and COX-1 and 2 were also performed. The tested doses of EB7 (4, 20 and 40 mg/kg) did not show any toxic effect on Zfa during the 96h of analysis (LD50>40 mg/kg). They did not produce any alteration in the locomotor behavior of the animals. Furthermore, EB7 showed promising pharmacological effects as it prevented the nociceptive behavior induced by hypertonic saline, capsaicin, formalin and acid saline. EB7 had its analgesic effect blocked by amiloride involving the neuromodulation of ASICs in Zfa. In evaluating the anti-inflammatory activity, the edema induced by κ-carrageenan 3.5 % was reduced by the dose of 40 mg/kg of EB7 observed after the fourth hour of analysis, indicating an effect similar to that of ibuprofen. Molecular docking results indicated that EB7 exhibited better affinity energy when compared to ibuprofen control against the two evaluated targets binding at different sites in the cocrystallized COX-1 and 2 inhibitors.
The present invention discloses medication for treating cardiac ache and a preparation method thereof. Effective active substances of dried ginger are extracted by a supercritical carbon dioxide fluid extraction device, and a proper amount of anhydrous alcohol is added in dried ginger extract obtained by extraction to make dried ginger extract alcoholic solution. Beta-cyclodextrin powder is taken to make beta-cyclodextrin saturated water solution which is added with dried ginger extract alcoholic solution. Yellow dryness loosening solid powder is obtained through stirring, refrigerated storage, filtration, washing and dryness. The made yellow dryness loosening solid powder is added with a proper amount of adhesive (1% PVP ethanol solution), and is made to mini-pills by a rolling method. The mini-pill is divided into three parts and is respectively coated with stomach solution coating (pH is from 1 to 2), intestine solution coating (PH is from 5 to 7) and segmented intestine solution coating (pH is from 10 to 12), which are uniformly mixed and encapsulated. The recipe and the preparation method of the present invention are peculiar, and the curative effect is significant.